RGNX — REGENXBIO Inc. stock price, charts and financials

Latest market price

10.48

-0.24-2.22%

Overview Short InterestFilings

RGNXQT59REGENXBIO Inc.·NASDAQ

Overview Short InterestFilings

10.48-2.22%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.52%$15.45 MESO+4.71%$16.69 ZBIO-0.93%$32.13 GHRS-1.77%$29.73 TSHA-1.59%$6.46 STOK-1.28%$32.29 ABCL+38.89%$9.63 VRDN-3.05%$22.87

Snapshot

Index	-	P/E	-	EPS (ttm)	-5.60	Insider Own	8.66%	Shs Outstand	51.70M	Perf Week	10.63%

Market Cap	554.20M	Forward P/E	-	EPS next Y	-2.84	Insider Trans	-1.76%	Shs Float	44.45M	Perf Month	-31.50%

Enterprise Value	586.66M	PEG	0.07	EPS next Q	-	Inst Own	-	Short Float	19.41%	Perf Quarter	2.88%

Income	-192.25M	P/S	3.18	EPS this Y	48.56%	Inst Trans	-	Short Ratio	4.40	Perf Half Y	4.48%

Sales	174.48M	P/B	7.89	EPS next Y	1.50%	ROA	-50.81%	Short Interest	8.63M	Perf YTD	-25.56%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-220.07%	52W High	15.83 -33.79%	Perf Year	30.26%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-51.50%	52W Low	5.34 96.34%	Perf 3Y	-43.28%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	14.58% 1.86%	Gross Margin	54.22%	Volatility	6.87% 7.60%	Perf 5Y	-66.83%

Dividend TTM	-	EV/Sales	3.36	EPS Y/Y TTM	-22.00%	Oper. Margin	-94.08%	ATR (14)	0.89	Perf 10Y	29.63%

Dividend Ex-Date	-	Quick Ratio	2.86	Sales Y/Y TTM	4.82%	Profit Margin	-112.58%	RSI (14)	51.63	Recom	2.30

Dividend Gr. 3/5Y	-	Current Ratio	2.86	EPS Q/Q	-1533.33%	SMA20	1.74%	Beta	0.91	Target Price	19.43

Payout	0.00%	Debt/Eq	0.96	Sales Q/Q	-93.26%	SMA50	8.55%	Rel Volume	0.61	Prev Close	10.72

Employees	371	LT Debt/Eq	2.06	Earnings	Nov 11	SMA200	1.81%	Avg Volume	2.25M	Price	10.48

IPO Date	Sep 17, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-28.65% -75.26%	Net Debt/EBITDA	-0.23	Volume	1,386,329	Change	-2.22%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-07-26	Reiterated	Morgan Stanley	Overweight	$16 → $18
Jul-01-26	Reiterated	H.C. Wainwright	Buy	$30 → $26
Jun-22-26	Reiterated	Robert W. Baird		$27 → $32
Jun-22-26	Reiterated	Leerink Partners	Outperform	$20 → $18
May-15-26	Reiterated	Morgan Stanley	Overweight	$17 → $16
May-15-26	Reiterated	Barclays	Overweight	$37 → $12
Mar-09-26	Reiterated	HC Wainwright & Co.	Buy	$32 → $30
Feb-10-26	Reiterated	Robert W. Baird		$39 → $27
Feb-10-26	Reiterated	UBS	Buy	$25 → $18
Feb-10-26	Reiterated	HC Wainwright & Co.	Buy	$34 → $32

Latest News

Aug-07-26

Aug-07-2603:20PM

This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For FridayBenzinga

07:05AM

REGENXBIO Q2 Earnings Call Highlightsmarketbeat.com

Aug-06-26

Aug-06-2605:14PM

REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcriptseekingalpha.com

10:51AM

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimateszacks.com

07:05AM

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlightsprnewswire.com

Aug-03-26

Aug-03-2607:05AM

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlightsprnewswire.com

Jul-31-26

Jul-31-2605:34PM

uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter CourseSeekingAlpha

Jul-23-26

Jul-23-2606:46AM

New Strong Sell Stocks for July 23rdzacks.com

Jul-21-26

Jul-21-2607:29PM

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firmprnewswire.com

03:52PM

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s WhyBenzinga

Jul-20-26

Jul-20-2610:45AM

Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatmentsbenzinga.com

Jul-18-26

Jul-18-2602:55PM

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meetingprnewswire.com

Jul-17-26

Jul-17-2607:00AM

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrantsprnewswire.com

Jul-16-26

Jul-16-2609:00PM

Thursday's after hours session: top gainers and losersChartMill

04:26PM

REGENXBIO Announces Proposed Public Offering of Common Stockprnewswire.com

Company

REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	174	170	83	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	80	20	34	—	—	—	—	—	—
Gross Profit	94	150	50	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	85	83	77	—	—	—	—	—	—
Research and Development	229	228	209	—	—	—	—	—	—
Other Operating Expense	-55	0	-3	—	—	—	—	—	—
Operating Income	-164	-161	-233	—	—	—	—	—	—
Interest Expense	42	45	13	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	10	12	19	—	—	—	—	—	—
Net Income Before Taxes	-196	-194	-227	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-196	-194	-227	—	—	—	—	—	—
Net Income From Continuing Operations	-196	-194	-227	—	—	—	—	—	—
Net Income	-196	-194	-227	—	—	—	—	—	—
EPS (Recurring)	-3.79	-3.76	-4.59	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-3.79	-3.76	-4.59	—	—	—	—	—	—
EPS (Diluted)	-3.79	-3.76	-4.59	—	—	—	—	—	—
EBITDA	-139	-133	-198	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	3.19	4.40	4.66	—	—	—	—	—	—
Gross Margin	54.02	88.24	60.24	—	—	—	—	—	—
Operating Margin	-94.25	-94.71	-280.72	—	—	—	—	—	—
Net Margin	-112.64	-114.12	-273.49	—	—	—	—	—	—
Shares Outstanding	53	52	50	—	—	—	—	—	—
Market Capitalization	556	749	387	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PAKOLA STEVE	Chief Medical Officer	Jul 02 '26	Option Exercise	7.86	2,161	16,985	215,170	Jul 06
PAKOLA STEVE	Chief Medical Officer	Jul 02 '26	Sale	13.64	2,161	29,476	213,009	Jul 06
PAKOLA STEVE	Chief Medical Officer	Jul 01 '26	Option Exercise	7.86	36,725	288,659	249,734	Jul 01
PAKOLA STEVE	Chief Medical Officer	Jul 01 '26	Sale	12.86	36,725	472,284	213,009	Jul 01
PAKOLA STEVE	Chief Medical Officer	Jun 29 '26	Sale	11.04	19,608	216,472	213,009	Jul 01
PAKOLA STEVE	Chief Medical Officer	May 11 '26	Sale	11.02	15,309	168,705	232,617	May 13
PAKOLA STEVE	Chief Medical Officer	Mar 10 '26	Sale	10.35	5,124	53,033	247,926	Mar 12
Mills Kenneth T.	Director	Jan 27 '26	Option Exercise	13.09	225,000	2,945,250	707,871	Jan 29
Simpson Curran	Chief Executive Officer	Oct 09 '25	Sale	12.62	20,811	262,635	216,162	Oct 10
Simpson Curran	Chief Executive Officer	Sep 29 '25	Sale	10.03	7,624	76,469	236,973	Oct 01
Simpson Curran	Chief Executive Officer	Sep 10 '25	Sale	10.02	7,734	77,495	244,597	Sep 12
Mills Kenneth T.	Director	May 12 '25	Option Exercise	3.76	20,602	77,464	495,705	May 14
Mills Kenneth T.	Director	May 12 '25	Sale	7.91	20,602	163,046	475,103	May 14
Mills Kenneth T.	Director	Mar 27 '25	Option Exercise	3.76	30,752	115,628	475,103	Mar 31
KARABELAS ARGERIS N	Director	Oct 01 '24	Option Exercise	3.76	10,000	37,600	21,286	Oct 02

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.